Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.
The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
It's the experiences we bring to life, rather than the things we create, that build value, gain trust, and earn loyalty.
Our understanding of how cancer develops and thrives has grown.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?
Porter Novelli has been appointed to lead a new global CSR brief for pharma and consumer goods giant Johnson & Johnson, as the company faces a major reputation challenge in the US.
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
The Paris-based pharma company debuted a brand campaign and signature last week.
Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.
Like its consumer-products cousins, pharma marketers are exercising more discipline over online media. Will it yield similar results?
AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.
The e-giant is reportedly doing everything from starting secret labs and online pharmacies to redefining the hospital experience and democratizing health data.
The answer: it depends on what phase the trial is in.
They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry's drug-pricing practices.
Novartis CEO Joe Jimenez to step down; Sanofi ends R&D plans for Zika vaccine; oncologists still struggle to predict metastasis
Condé Nast, Time Inc., and Vice Media have all recently launched health content businesses.
The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
The CEO of Huntsworth's biggest and fastest-growing unit Huntsworth Health, which includes Nitrogen and Tonic Life, has departed after eight years.